- KR₩42tn
- KR₩45tn
- KR₩4tn
Brief: FDA Approves Expanded Indication For Avtozma® Intravenous Formulation In Cytokine Release Syndrome
South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk (updated)
South Korea's Celltrion says is preferred bidder to acquire pharma company to offset US tariff risk
Brief: Celltrion To Buy Back 100 Billion Won Worth Shares
Brief: Celltrion Inc To Issue 8.5 Million Bonus Shares
South Korea vows more support measures over US tariffs, including for drugmakers (updated)
Brief: Celltrion Inc To Buy Back 100 Billion Won Worth Shares
Brief: Celltrion To Cancel Its Own Shares Worth 98.5 Billion Won
Brief: Shilpa Medicare Enters Into Settlement With Celltrion
Brief: Celltrion Inc To Acquire 50 Billion Won Worth Of Its Own Shares
Brief: Celltrion Submits Plan For Phase 3 Clinical Trials For Darzalex Biosimilar Ct-P44 To South Korean Regulator
Brief: U.S. FDA Approves Celltrion Inc's Omlyclo, Biosimilar To Xolair
South Korean shares end marginally higher amid mixed earnings
Brief: Celltrion To Buy Back 100 Billion Won Worth Of Own Shares
Brief: Celltrion Inc Signs 100 Billion Won Supply Contract
Brief: Celltrion Inc Has Applied To European Medicines Agency For Phase 3 Clinical Trial Of Ct-P55, Biosimilar To Novartis' Cosentyx To Treat Plaque Psoriasis
Brief: Celltrion Inc Receives Final Market Approval For Steqeyma, Used For The Treatment Of Paediatric Plaque Psoriasis, Psoriatic Arthritis, And Crohn’S Disease From The European Commission
Brief: Celltrion Inc Q2 Consolidated Operating Profit 72.5 Billion Won, Down 60.4% From Year Earlier
Brief: Celltrion Inc To Acquire 75 Billion Won Worth Of Own Shares